News

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...
Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...